DMAC News and Press, DiaMedica Therapeutics Inc. From 01/29/24

DiaMedica Presents the Protocol and Rationale for ReMEDy2, a Pivotal Trial in Patients Suffering Acute Ischemic Stroke Ineligible for tPA and/or Mechanical Thrombectomy DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developi...

2024-01-22 08:31:49 ET More on DiaMedica Therapeutics Seeking Alpha’s Quant Rating on DiaMedica Therapeutics Historical earnings data for DiaMedica Therapeutics Financial information for DiaMedica Therapeutics For further details see: DiaMedica The...

Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the...

2023-11-14 12:10:06 ET DiaMedica Therapeutics Inc. (DMAC) Q3 2023 Earnings Call Transcript November 14, 2023 08:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capita...

2023-11-13 16:38:01 ET More on DiaMedica Therapeutics DiaMedica appoints Ambarish Shah, Ph.D. as CTO Seeking Alpha’s Quant Rating on DiaMedica Therapeutics Historical earnings data for DiaMedica Therapeutics Financial information for DiaMedica Therapeu...

Conference Call and Webcast November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Updated Amendment to Phase 2/3 ReMEDy2 AIS Protocol Aimed at Enhancing Patient Enrollment and Increasing Probability of Study Success, 30-Day FDA Review Period Passed Without Comment ReMEDy2...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

DiaMedica Therapeutics Inc. (DMAC) is expected to report $-0.14 for Q3 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, today announced that Rick Pauls, its President and CEO and Dave Wambeke, its Chief Business Officer will be p...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its third quarter 2023 financial results will be released after the markets close on Mon...